Turalio (pexidartinib) — Medica
Histiocytic neoplasms with CSF1R mutation (Langerhans cell histiocytosis, Erdheim-Chester disease, or Rosai-Dorfman disease)
Initial criteria
- age ≥ 18 years
- colony stimulating factor 1 receptor (CSF1R) mutation present
- diagnosis is one of the following: Langerhans cell histiocytosis OR Erdheim-Chester disease OR Rosai-Dorfman disease
Approval duration
1 year